J9266 Pegaspargase Injection HCPCS Reimbursement

HCPCS Level II code J9266 denotes the per-vial injection of pegaspargase, a pegylated L-asparaginase formulation used in oncology regimens, particularly for treatment of acute lymphoblastic leukemia. This code is important for accurate reporting of high-cost antineoplastic agents administered by infusion or injection in outpatient and office-based settings. Nationally, proper coding of J9266 affects coverage determinations, prior authorization workflows, and cost reporting for payers that cover specialty oncology therapies.

Key payers reviewed in this context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service settings for J9266, typical payer coverage patterns, common modifiers used in billing, and related operational considerations for hospital outpatient departments and infusion clinics. The publication also highlights benchmark concepts important to billing teams, such as per-vial reporting, site-of-service implications, and documentation elements that support medical necessity.

This summary provides clinicians, billing professionals, and policy staff with the essential information needed to understand what J9266 represents, how it is used in care delivery, and which national payers are commonly involved in coverage and payment processes. Data not available in the input is noted where applicable.

Billing Code Overview

HCPCS Level II code J9266 represents an injection of pegaspargase supplied per single-dose vial. This code is used to report administration of the pegylated form of L-asparaginase, commonly used in oncology treatment regimens for certain leukemias.

Service type: Parenteral chemotherapy/antineoplastic drug administration
Typical site of service: Hospital outpatient department, physician office (oncology/infusion clinic), or ambulatory infusion center

Clinical Context

A pediatric or young adult patient with newly diagnosed or relapsed acute lymphoblastic leukemia (ALL) receives chemotherapy that includes pegaspargase administered as an intravenous injection. The typical workflow begins in an outpatient oncology infusion center or inpatient oncology unit: the oncology nurse verifies the physician order and allergy history, obtains baseline labs including liver function tests, coagulation profile, and pancreatic enzymes, and confirms venous access. The pharmacist compounds the weight‑based pegaspargase dose in a single‑dose vial and verifies stability and concentration. The nurse administers pegaspargase via IV push or short infusion per institutional protocol, monitors for hypersensitivity reactions for at least 30–60 minutes, documents lot number and vial size, and records administration using the HCPCS code J9266. Follow‑up includes scheduled lab monitoring and coordination of subsequent chemotherapy cycles.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded (wasted)	Use when a portion of from the single‑dose vial is discarded and the payer requires reporting of discarded biologic drug.

Taxonomy Code	Specialty	Notes
`208000000X`	Hematology & Medical Oncology	Oncology specialists who prescribe and supervise `pegaspargase` therapy.
`207Q00000X`	Pediatric Hematology‑Oncology	Pediatric specialists who commonly administer `pegaspargase` for childhood ALL.
`163W00000X`	Nurse Practitioner	Advanced practice clinicians who may order and manage chemotherapy administration.
`363A00000X`	Clinical Pharmacist	Pharmacists who prepare and verify chemotherapy doses and document lot numbers and concentrations.
`174400000X`	Oncology Nurse	Registered nurses who administer IV chemotherapy and monitor for infusion reactions.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C91.0`	Acute lymphoblastic leukemia, not having achieved remission	ALL is the primary indication for `pegaspargase` in induction or salvage chemotherapy.
`C91.1`	Acute lymphoblastic leukemia, in remission	Used when maintenance or consolidation therapy includes `pegaspargase` in protocols for patients in remission.
`C92.0`	Acute myeloblastic leukemia, not having achieved remission	Included when protocol‑driven use occurs in mixed or investigational regimens (less common).
`C83.3`	Burkitt lymphoma	`Pegaspargase` can be used in certain lymphoma regimens where asparaginase activity is indicated.
`D61.9`	Aplastic anemia, unspecified	Listed for monitoring contexts where cytopenias affect chemotherapy decisions; not a direct indication for `pegaspargase`.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, IV infusion technique; infusion of a single chemotherapeutic agent, up to 1 hour	Commonly used for administration of IV chemotherapy agents; may be used if `pegaspargase` is given as an infusion.
`96415`	Chemotherapy administration, IV infusion technique; each additional hour (List separately in addition to code for primary infusion)	Used when prolonged infusion monitoring or extended infusion time is required beyond the initial hour.
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	May apply for initial IV push/infusion of supportive medications or hydration given with `pegaspargase`.
`96374`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential infusion of the same drug, different site (List separately in addition to code for primary infusion)	Used if multiple separate injections/infusions are administered during the same visit.
`36415`	Collection of venous blood by venipuncture	Used for pre‑ and post‑administration laboratory testing to monitor hepatic function, coagulation, and pancreatic enzymes.

OpenPayer

Summary & Overview

HCPCS J9266: Injection, Pegaspargase, Single-Dose Vial